In this sense, although we did not find significant differences in serum SFRP5 levels between patients with or without NAFLD, we reported increased hepatic mRNA abundance of SFRP5 in patients with SS in contrast to those with NL or NASH. The gene discussed is SFRP5; the disease is metabolic dysfunction-associated steatotic liver disease.